Kenvue

Kenvue AAQS

The The AAQS of Kenvue (KVUE) as of Nov 4, 2026 is 1. In the previous year, The AAQS was 1.00 — a change of 0.00% (lower).

AAQS

1

YoY

0.00%

Last updated:

Kenvue has a current AAQS of 1.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Kenvue in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Kenvue AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2019
1.00 USD
Jan 1, 2020
1.00 USD
Jan 1, 2021
1.00 USD
Jan 1, 2022
1.00 USD
Jan 1, 2023
1.00 USD
Jan 1, 2024
1.00 USD
Jan 1, 2025
1.00 USD
The Kenvue AAQS history
YEARAAQSYoY
10.00%
10.00%
10.00%
10.00%
10.00%
10.00%
1—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kenvue Stock analysis

What does Kenvue do? Kenvue Inc. generates revenue through its three business segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment sells products like Tylenol for pain care, Zyrtec for allergies, and Nicorette for smoking cessation. The Skin Health and Beauty segment offers Neutrogena face and body care, Listerine for oral hygiene, and Aveeno for skin health. Essential Health includes Johnson’s baby care, Band-Aid for wound care, and oral care products. These brands target consumers globally across 165 countries, with distribution via 114 centers and 38 customer service hubs. Kenvue’s differentiated brand portfolio drives sales, with Tylenol, Neutrogena, and Listerine as key products. The Self Care segment focuses on cough, cold, and allergy remedies, while Skin Health and Beauty emphasizes face and body care. Essential Health covers oral care, baby care, and women’s health products. The company serves consumers directly through retail channels in all regions, leveraging its global distribution network. The company’s revenue streams come from selling its branded products in self-care, skin health, and essential health categories. Tylenol leads in pain care, Neutrogena dominates face and body care, and Johnson’s is prominent in baby care. Brands like Listerine and Aveeno cater to oral and skin health needs, while Band-Aid addresses wound care. Sales occur across 165 countries through 114 distribution centers and 38 customer service centers. Kenvue is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kenvue stock

The AAQS of Kenvue is 1 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Kenvue since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Kenvue

All Key Metrics — Kenvue